ACRS - CIK 0001557746
The table below shows Aclaris Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.66M | $25.26M | $25.40M | $30.36M | $47.65M | $22.83M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | $194.00K | $250.00K | $343.00K | $325.00K |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $110.23M |
| $100.59M |
| $104.20M |
| $108.79M |
| $132.33M |
| $117.64M |
| Property, plant & equipment | $750.00K | $811.00K | $868.00K | $942.00K | $1.13M | $1.29M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $198.72M | $175.53M | $189.15M | $198.09M | $182.39M | $161.07M |
| Accounts payable | $14.73M | $9.19M | $8.80M | $6.35M | $7.66M | $7.27M |
| Total current liabilities | $27.37M | $25.63M | $26.84M | $21.51M | $18.82M | $15.68M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $55.07M | $55.43M | $57.41M | $54.03M | $52.24M | $27.25M |
| Retained earnings | -$987.61M | -$947.99M | -$933.38M | -$917.95M | -$806.31M | -$798.72M |
| Total equity | $143.65M | $120.10M | $131.74M | $144.07M | $130.15M | $133.82M |